Subclinical AKI can be identified with novel biomarkers, and in this category, cell-cycle arrest urinary biomarkers, such as insulin-like growth factor-binding protein 7 (IGFBP7) and tissue inhibitor of metalloproteinases-2 (TIMP2), have been shown to have a superior profile of accuracy and stability, even in patients with common comorbidities [11]. This evidence concerns the gene TIMP2 and acute kidney injury.